Tag: LIMITED

JAKARTA, Indonesia, June 16, 2026 /PRNewswire/ -- OMOWAY announced the delivery of the world's first batch of OMO-X motorcycles in Indonesia on June 15....

Launching a resort-wide "Wing Lei Bar & Friends" Special Edition, Wynn will unite over 50 global mixology and culinary visionaries from July 24 to 29MACAO,...

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

New Tyvek® innovation designed to support worker safety and comfort across ASEANBANGKOK, June 16, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced that it...

MUNICH, June 16, 2026 /PRNewswire/ -- Innovative Molecules GmbH ("IM"), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, today announced the advancement of its virology...

162 million 5G subscriptions added during the first quarter of 2026, bringing the total to 3.1 billionThe number of commercial differentiated connectivity service offerings...

AS LHV Group’s May financial results reflected positive performance, with the results of all subsidiaries in line with the financial plan. LHV Group earned a consolidated net profit of EUR 9.1 million in May, with return on equity attributable to shareholders of 14.1%. Among the subsidiaries, AS LHV Pank earned EUR 9.8 million, LHV Bank Ltd EUR 0.3 million, AS LHV Varahaldus EUR 0.2 million and AS LHV Kindlustus EUR 0.4 million in net profit.

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

KUALA LUMPUR, Malaysia, June 16, 2026 /PRNewswire/ -- Amaron, the flagship battery brand from Amara Raja Energy & Mobility Limited, is set to strengthen its...

SYDNEY, June 15, 2026 /PRNewswire/ -- Bifox Limited ("Bifox") is pleased to advise it has entered into two agreements with Fossal S.A.A ("Fossal"), to...

/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/SASKATOON, SK, June 15, 2026 /CNW/ - Wescan Goldfields Inc. (TSXV: WGF)...

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

MONTREAL, June 15, 2026 /CNW/ -- Tecsys Inc. (TSX: TCS) will release its financial results for the fourth quarter and fiscal year 2026 ended April...

Terra Innovatum Global N.V. (NASDAQ: NKLR) Files 2025 Form 10‑k and Reports Fourth Quarter and Fiscal Year 2025 Financial Results